After Hours Decliner
TENX Tenax Therapeutics14.26+2.81+24.5%
After Hours:10.94-3.32 (-23.3%)
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Globe NewswireWed, 7-Feb 8:01 PM
Premarket Gainer
TENX Tenax Therapeutics1.780.000.0%
Premarket:2.68+0.90 (+50.6%)
Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med
Business WireTue, 19-Jan 7:45 AM
